Our Cox model allowed us to explore the risk for pancreatic cancer associated with use of GLP-1RA compared with basal insulin, with all other characteristics being equal, including history of pancreatitis, other glucose-lowering drugs, and length of diabetes. Here, INS is linked to pancreatitis.